Each person’s cancer is unique. The treatment journey should be too.

Cancer has a devastating impact on those living with the disease and their loved ones, and oncologists face major challenges as they work to deliver effective care tailored to each patient. On average, 75% of cancer patients will not respond to a particular drugs in a class of agents. It’s no wonder that oncologists are increasingly looking to genomics insights to identify more precise and potentially effective therapies.1

Now, through partnerships with Quest Diagnostics & Illumina, deep cancer expertise from over 20 leading healthcare institutions, and the genomics sequencing capabilities of Broad Institute of MIT and Harvard, we have an opportunity to help oncologists identify personalized approaches to cancer treatments for their patients.

Watson Genomics from Quest Diagnostics® is only available through a practicing oncologist and may not be appropriate for all types of cancer.

If you are a patient interested in Watson Genomics from Quest Diagnostics®, please speak with your oncologist to determine if this test may be right for you.

Product key features

Your cancer, your treatment

Once you and your doctor determine that Watson Genomics from Quest Diagnostics® is the right approach for your cancer, a tissue sample from your tumor will be sent to Quest to undergo gene sequencing to determine which genetic alterations it may have. Quest then uploads the sequenced genetic file to Watson for Genomics to provide them with information to help them identify mutations in your cancer that are potentially treatable, and these insights could then help your doctor identify targeted treatments for you.

Information to help enhance confidence

In addition to providing information regarding your tumor’s genetic alterations, Watson for Genomics also draws evidence from a vast corpus of medical literature, as well as MSK’s OncoKB, a precision oncology knowledge base. A comparison that may typically take a team of medical experts weeks to prepare can now be completed in significantly less time. This can help clinicians and their patients and cancer care teams feel more confident about the path forward with an evidence-based, individualized care plan.

Providing clinicians with information to help them deliver patient-centric care with personalized medicine at scale.

As an oncology professional you are tirelessly working to adjust to an evolving healthcare landscape and innovative new treatment options. On top of fiscal challenges, every day brings more published research, and data to analyze and incorporate into your practice, making the ability to draw highly specific, relevant insights more critical and difficult than ever.

Watson for Genomics provides licensed physicians with an analytic tool to help them quickly locate relevant information regarding potential targeted therapeutic options. A clinician uploads a patient’s tumor sequencing results into Watson for Genomics and it helps analyze the patient’s genomic data by providing information on potential therapeutic options with supporting evidence for the clinician’s consideration.

Learn more about how Watson Genomics from Quest Diagnostics can help you deliver more personalized care.

Watson Genomics from Quest Diagnostics®

In partnership with Quest Diagnostics’ state-of-the-art tumor analysis, combined with the deep cancer expertise of Memorial Sloan Kettering Cancer Center (MSK), and additional genome sequencing capabilities provided by the Broad Institute of MIT and Harvard, Watson Genomics from Quest Diagnostics® can help provide clinicians with a solution that can give them the ablility to offer genomic testing at scale, and information that can allow every oncologist access to personalized, patient-centric therapeutic options.

If you’re a healthcare professional who wants to help bring the power of personalized medicine to your practice, learn more about Watson Genomics from Quest Diagnostics®.

If you are a clinician already conducting genetic sequencing and would like to learn more about using Watson for Genomics, let us know.

Product key features

Information regarding actionable therapeutic options

Quest Diagnostics sequences and analyzes your patients’ tumors’ genomic makeup to help you understand the unique cancer-causing mutations specific to each individual’s sample. The test identifies base pair substitutions, insertions and deletions, copy number variations and select translocations through full-gene sequencing of 50 genes that have been determined to yield the most currently actionable mutations. A Quest Diagnostics medical director will review and validate the results and prepare a report that delivers information to the treating clinician regarding potential personalized, targeted therapeutic options.

Information to help enhance clinical confidence

In addition to providing information regarding your patients’ tumors’ genetic alterations, Watson Genomics from Quest Diagnostics® also provides supporting evidence from a vast corpus of relevant medical literature, as well as MSK’s OncoKB, a precision oncology knowledge base. A comparison that could take an oncology board weeks to prepare can now be completed in significantly less time.

Broader data for a more personalized approach

By leveraging the cognitive power of Watson for Genomics to help analyze both structured and unstructured data and information, Watson for Genomics can help compare these informational sources as they relate to your patients’ unique situations to provide a comprehensive, personalized approach.

Watson is helping cancer care teams around the world implement a more patient-centric cancer care model.

Explore our other oncology and genomics offerings

IBM Watson for Clinical Trial Matching

Watson for Clinical Trial Matching eliminates the need to manually compare enrollment criteria with patient medical data, making it possible to efficiently screen cancer patients and identify their potential trial options with one simple solution.

IBM Watson for Oncology

Watson for Oncology helps physicians quickly make sense of their patient’s longitudinal health record, surface relevant articles, and explore treatment options to reduce the variability of care and give time back to their patients.

Explore the latest genomics news

1The Case for Personalized Medicine, 4th Edition, 2014, accessed on 9/8/16, available at www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/pmc_the_case_for_personalized_medicine.pdf (PDF, 1.3MB)